Psilocybin

Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor

Monday, July 26, 2021 - 2:43pm

Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.

Key Points: 
  • Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.
  • Tryp is also announcing the appointment of Daniel Clauw, M.D., as a member of the Scientific Advisory Board.
  • We welcome their continued scientific leadership as we advance the development of our PFN program toward approved therapies for patients."
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Wednesday, July 21, 2021 - 12:00pm

The study is expected to be the world's first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia

Key Points: 
  • The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
  • The Principal Investigator for the trial will be Kevin Boehnke, Ph.D., Research Investigator, University of Michigan Department of Anesthesiology.
  • Tryp expects to submit the Investigational New Drug (IND) application to the FDA for the Phase 2a clinical trial in 3Q 2021.
  • The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

NEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4%  and 20.6% of the adult population respectively. As psychedelics gain more recognition, companies such as Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Seelos Therapeutics (NASDAQ:SEEL), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), and Mydecine Innovations Group Inc. (NEO:MYCO) (OTCPK:MYCOF) are engaging in research initiatives to develop psychedelic-assisted therapies for different mental illnesses and chronic pain conditions.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients

Tuesday, July 20, 2021 - 12:31pm

Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Key Points: 
  • Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • Braxia develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Global Wellness Strategies and Cannvalate AU Sign Revolutionary Psychedelic Deal

Monday, July 19, 2021 - 1:30pm

Solving the Puzzle of Pain with MDMA Medicines

Key Points: 
  • Additionally, Cannvalate jointly owns a Contract Research Organisation with a major Australian university specialising in cannabinoid and psychedelic clinical trials which has been researching psychedelic solutions for several years.
  • Cannvalate holds an Australian import license and license to supply schedule 8 poisons (including MDMA and Psilocybin).
  • Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products.
  • The focus of the Company is on global wellness, psilocybin, mycology, hemp and CBD, healthcare-related target companies.

Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021

Sunday, July 18, 2021 - 12:00am

The Virtual Town Hall event will comprise of a presentation by Dr. Hancock on the status of Vocans production of biosynthetic psilocybin and will include live video from the Companys operating laboratory in Victoria, British Columbia.

Key Points: 
  • The Virtual Town Hall event will comprise of a presentation by Dr. Hancock on the status of Vocans production of biosynthetic psilocybin and will include live video from the Companys operating laboratory in Victoria, British Columbia.
  • 2021 has been a significant year for Core One Labs, and our teams have been very focused on building a company that we truly feel sets precedent in the psychedelics space.
  • The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.
  • Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

Wednesday, July 7, 2021 - 12:30pm

There is a growing body of supporting evidence that suggests MSP-1014 will deliver superior efficacy and an improved safety profile compared to generic psilocybin, said Joseph Araujo, Chief Scientific Officer of Mindset.

Key Points: 
  • There is a growing body of supporting evidence that suggests MSP-1014 will deliver superior efficacy and an improved safety profile compared to generic psilocybin, said Joseph Araujo, Chief Scientific Officer of Mindset.
  • One critical pre-clinical study we used to assess MSP-1014s potential superior efficacy compared to psilocybin was 5-HT2A receptor activity.
  • To assess this activity, we compared MSP-1014 to psilocybin using the mouse head twitch response (HTR) assay.
  • For additional detail on our Family 1 lead candidate MSP-1014, please watch the following interview from Mindsets management team: https://youtu.be/ZWl14TPzAek .

Braxia Scientific to Discuss Psychiatric Treatment Discovery and Development with Oxford University Researchers at AIMday Experimental Medicine in Psychiatry on July 7, 2021

Wednesday, July 7, 2021 - 12:45pm

Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of "How can we advance treatment discovery and development in psychiatry targeting cognition?"

Key Points: 
  • Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of "How can we advance treatment discovery and development in psychiatry targeting cognition?"
  • Participating companies include: Braxia Scientific, Lundbeck, Compass Pathways, P1vital, Circadian Therapeutics, Zogenix, Cyclica, Precision Life, Beckley Psytech, BrainBerry, Braincures, BrainPatch, Psious, Jazz Pharmaceuticals & Ranvier Health.
  • The medical solutions company aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Inclu

Wednesday, July 7, 2021 - 12:00pm

Dr. Ross is an Associate Professor of Psychiatry at NYU Langone, and the Associate Director of its newly designated Center for Psychedelic Medicine.

Key Points: 
  • Dr. Ross is an Associate Professor of Psychiatry at NYU Langone, and the Associate Director of its newly designated Center for Psychedelic Medicine.
  • Dr. Ross research principally focuses on the use of psilocybin and related psychedelics for the treatment of mood disorders in patients with life-threatening cancer.
  • As part of the collaboration, the parties will continue to explore the role of psychedelics in the treatment of mental illness in other life-threatening disorders, in addition to cancer.
  • Importantly, we believe that psilocybin is a promising treatment for anxiety and depression in patients with life-threatening cancer, increasing therapeutic opportunities.